Description: Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
Home Page: www.gamida-cell.com
GMDA Technical Analysis
5 Nahum Heftsadie Street
Jerusalem,
91340
Israel
Phone:
972 2 659 5666
Officers
| Name | Title |
|---|---|
| Mr. Shai Lankry CPA, M.B.A. | Chief Financial Officer |
| Ms. Michele Ilene Korfin M.B.A., R.Ph. | Chief Operating & Chief Commercial Officer |
| Dr. Ronit Simantov M.D. | Chief Medical & Chief Scientific Officer |
| Ms. Abigail L. Jenkins | Pres, CEO & Director |
| Mr. Joshua F. Patterson | Gen. Counsel & Chief Compliance Officer |
| Mr. Paul Nee | VP of Marketing |
| Mr. Naftali Brikashvili CPA | Sr. VP Fin. & Operations |
| Dr. Tracey Lodie Ph.D. | Scientific Advisor & Consultant |
| Mr. Vladimir Melnikov | Sr. VP of Global Operations & Manufacturing |
| Heather DiVecchia | Chief of Staff |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.3498 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-10-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 166 |